PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling

Journal of Bone and Mineral Research

Volumn 26, Issue 5, 2011, Pages 1035-1046

  Rhee, Yumie ^a,c   Allen, Matthew R ^a   Condon, Keith ^a   Lezcano, Virginia ^a,d   Ronda, Ana C ^a,d   Galli, Carlo ^a,e   Olivos, Naomi ^a   Passeri, Giovanni ^a,e   O'Brien, Charles A ^b   Bivi, Nicoletta ^a   Plotkin, Lilian I ^a   Bellido, Teresita ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

INTRACORTICAL REMODELING; OSTEOCYTES; PERIOSTEAL BONE FORMATION; PTH RECEPTOR; WNT SIGNALING

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; SCLEROSTIN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE REMODELING; CORTICAL BONE; GENE TARGETING; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; PERIOSTEUM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; CYTOKINES; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; LDL-RECEPTOR RELATED PROTEINS; MICE; MICE, TRANSGENIC; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOGENESIS; PERIOSTEUM; PHENOTYPE; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SIGNAL TRANSDUCTION; SKULL; WNT PROTEINS;

EID: 79955578020     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.304     Document Type: Article

References (50)

1. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK,. Bone loss and bone size after menopause. N Engl J Med. 2003; 349: 327-334. (Pubitemid 36886238)
2. Orwoll ES,. Toward an expanded understanding of the role of the periosteum in skeletal health. J Bone Miner Res. 2003; 18: 949-954. (Pubitemid 37294930)
3. Crabtree N, Loveridge N, Parker M, et al. Intracapsular hip fracture and the region-specific loss of cortical bone: analysis by peripheral quantitative computed tomography. J Bone Miner Res. 2001; 16: 1318-1328. (Pubitemid 32574661)
4. Beck TJ, Ruff CB, Scott WW Jr, Plato CC, Tobin JD, Quan CA,. Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int. 1992; 50: 24-29.
5. Duan Y, Seeman E, Turner CH,. The biomechanical basis of vertebral body fragility in men and women. J Bone Miner Res. 2001; 16: 2276-2283. (Pubitemid 33104719)
6. Kalender WA, Felsenberg D, Louis O, et al. Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography. Eur J Radiol. 1989; 9: 75-80. (Pubitemid 19147000)
7. Allen MR, Hock JM, Burr DB,. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone. 2004; 35: 1003-1012. (Pubitemid 39487345)
8. Parfitt AM,. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res. 2002; 17: 1741-1743.
9. Christiansen P, Steiniche T, Brockstedt H, Mosekilde L, Hessov I, Melsen F,. Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone. 1993; 14: 755-762. (Pubitemid 23294029)
10. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB,. Effects of a one-month treatment with parathyroid hormone (1-34) on bone formation on cancellous, endocortical and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22: 495-502. (Pubitemid 47457425)
11. Kneissel M, Boyde A, Gasser JA,. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone. 2001; 28: 237-250. (Pubitemid 32192948)
12. Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW,. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone. 2007; 40: 391-398. (Pubitemid 46054555)
13. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC,. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009; 44: 275-286.
14. Hirano T, Burr DB, Cain RL, Hock JM,. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int. 2000; 66: 456-460. (Pubitemid 30368377)
15. Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002; 17: 1570-1578.
16. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S,. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001; 142: 4349-4356. (Pubitemid 32907063)
17. Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone. 2009; 44: 113-119.
18. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY,. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007; 41: 321-330. (Pubitemid 47199143)
19. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM,. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16: 157-165. (Pubitemid 32046201)
20. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC,. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439-446. (Pubitemid 29534328)
21. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278: 50259-50272. (Pubitemid 37548867)
22. Jilka RL,. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40: 1434-1446. (Pubitemid 46756429)
23. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148-158. (Pubitemid 40962421)
24. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577-4583. (Pubitemid 41446595)
25. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3: e2942.
26. Kalajzic I, Braut A, Guo D, et al. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone. 2004; 35: 74-82. (Pubitemid 38789150)
27. Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA. 2005; 102: 17406-17411. (Pubitemid 41740879)
28. Erlebacher A, Derynck R,. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol. 1996; 132: 195-210.
29. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987; 2: 595-610.
30. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-19887. (Pubitemid 41379516)
31. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, et al. WNT/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006; 281: 31720-31728. (Pubitemid 46043263)
32. Neuman WF, Neuman MW, Sammon PJ, Casarett GW,. The metabolism of labeled parathyroid hormone. IV. Autoradiographic studies. Calcif Tissue Res. 1975; 18: 263-270.
33. Parfitt AM,. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism. 1976; 25: 909-955.
34. Seeman E,. Pathogenesis of bone fragility in women and men. Lancet. 2002; 359: 1841-1850. (Pubitemid 34607063)
35. Leupin O, Kramer I, Collette NM, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22: 1957-1967. (Pubitemid 351229312)
36. Glass DA, Karsenty G,. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007; 148: 2630-2634. (Pubitemid 46984774)
37. Baron R, Rawadi G,. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635-2643. (Pubitemid 46984775)
38. Choi HY, Dieckmann M, Herz J, Niemeier A,. Lrp4, a novel receptor for dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE. 2009; 4: e7930.
39. Li Y, Pawlik B, Elcioglu N, et al. LRP4 Mutations Alter Wnt/beta-Catenin Signaling and Cause Limb and Kidney Malformations in Cenani-Lenz Syndrome. Am J Hum Genet. 2010; 86: 696-706.
40. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825-837.
41. Cui Y, Niziolek PJ, MacDonald BT, et al. LRP5 functions in bone to regulate bone mass. Nat Med. 2011; (in press).
42. Calvi LM, Sims NA, Hunzelman JL, et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001; 107: 277-286. (Pubitemid 32157960)
43. Pyrah LN, Hodgkinson A, Anderson CK,. Primary hyperparathyroidism. Br J Surg. 1966; 53: 245-316.
44. Calvi LM, Shin HI, Knight MC, et al. Constitutively active PTH/PTHrP receptor in odontoblasts alters odontoblast and ameloblast function and maturation. Mech Dev. 2004; 121: 397-408. (Pubitemid 38510595)
45. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267-6276. (Pubitemid 37522584)
46. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928-935. (Pubitemid 40994212)
47. Fu Q, Jilka RL, Manolagas SC, O'Brien CA,. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of CREB. J Biol Chem. 2002; 277: 48868-48875. (Pubitemid 35470855)
48. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-764. (Pubitemid 40585297)
49. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005; 280: 21162-21168. (Pubitemid 40805677)
50. Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30: 3071-3085.